MX354846B - Metodos para tratar gota en sub-poblaciones de pacientes. - Google Patents

Metodos para tratar gota en sub-poblaciones de pacientes.

Info

Publication number
MX354846B
MX354846B MX2014005399A MX2014005399A MX354846B MX 354846 B MX354846 B MX 354846B MX 2014005399 A MX2014005399 A MX 2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A MX 354846 B MX354846 B MX 354846B
Authority
MX
Mexico
Prior art keywords
methods
treating gout
patient subpopulations
subject
subpopulations
Prior art date
Application number
MX2014005399A
Other languages
English (en)
Spanish (es)
Other versions
MX2014005399A (es
Inventor
Edward Lavan Brian
chandra saha Gopal
K Roberts Brian
A Mcwherter Charles
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2014005399A publication Critical patent/MX2014005399A/es
Publication of MX354846B publication Critical patent/MX354846B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014005399A 2011-11-04 2011-11-04 Metodos para tratar gota en sub-poblaciones de pacientes. MX354846B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
MX2014005399A MX2014005399A (es) 2015-04-08
MX354846B true MX354846B (es) 2018-03-22

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005399A MX354846B (es) 2011-11-04 2011-11-04 Metodos para tratar gota en sub-poblaciones de pacientes.

Country Status (14)

Country Link
EP (1) EP2775835A4 (OSRAM)
JP (1) JP6047172B2 (OSRAM)
KR (1) KR101848122B1 (OSRAM)
CN (1) CN104066323A (OSRAM)
AU (1) AU2011380509B2 (OSRAM)
BR (1) BR112014010693A2 (OSRAM)
CA (1) CA2859689C (OSRAM)
CL (1) CL2014001156A1 (OSRAM)
IL (1) IL232385A (OSRAM)
MX (1) MX354846B (OSRAM)
NZ (1) NZ624714A (OSRAM)
SG (1) SG11201402027PA (OSRAM)
WO (1) WO2013066352A1 (OSRAM)
ZA (1) ZA201403574B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (en) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc METHOD FOR THE TREATMENT OF HYPERURICEMIA IN PATIENTS WITH A GOG THROUGH HALOFENATE OR HALOFENIC ACID AND AN INFLAMMATORY INHIBITOR
CN104068288B (zh) * 2014-07-25 2016-08-24 许伟琦 一种防尿路结石的饲料添加剂
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN103058944B (zh) * 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物

Also Published As

Publication number Publication date
EP2775835A1 (en) 2014-09-17
CN104066323A (zh) 2014-09-24
IL232385A (en) 2017-10-31
IL232385A0 (en) 2014-06-30
NZ624714A (en) 2016-01-29
CA2859689A1 (en) 2013-05-10
BR112014010693A2 (pt) 2020-11-10
CL2014001156A1 (es) 2015-01-16
ZA201403574B (en) 2015-11-25
KR101848122B1 (ko) 2018-04-11
JP6047172B2 (ja) 2016-12-21
KR20140123927A (ko) 2014-10-23
MX2014005399A (es) 2015-04-08
WO2013066352A1 (en) 2013-05-10
AU2011380509A1 (en) 2014-05-29
EP2775835A4 (en) 2015-07-29
CA2859689C (en) 2018-05-22
SG11201402027PA (en) 2014-09-26
JP2014532759A (ja) 2014-12-08
AU2011380509B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
PH12013502144A1 (en) Multiple myeloma treatment
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
BR112013005810A2 (pt) métodos para reduzir a concentração de lactato no sangue
MX349373B (es) Nuevos derivados de pirazina.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
PH12014500990A1 (en) Methods for treating gout flares
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
GEP20166448B (en) Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
FR2980708B1 (fr) Composition comprenant un gallotannin
MX354846B (es) Metodos para tratar gota en sub-poblaciones de pacientes.
GB201107985D0 (en) Process
WO2012015255A3 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
MY172619A (en) Method for refining quinolinic acid
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
WO2013090319A3 (en) Treatment of type i and type ii diabetes
HUE036037T2 (hu) (3S,3S')4,4'-Diszulfándiil-bisz(3-aminobután-1-szulfonsav), azaz ABSD, L-lizinnel képezett kristályos alakja
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
MX2012003290A (es) Composicion para reducir el nivel de acido urico en la sangre.
MX338595B (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.
WO2011161295A3 (es) Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular

Legal Events

Date Code Title Description
FG Grant or registration